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Abstract
Despite recent advances in the field of Oncoimmunology, the success potential of immunomodulatory
therapies against cancer remains to be elucidated. One of the reasons is the lack of understanding
on the complex interplay between tumor growth dynamics and the associated immune system responses.
Towards this goal, we consider a mathematical model of vascularized tumor growth and the corresponding
effector cell recruitment dynamics. Bifurcation analysis allows for the exploration of model’s dynamic
behavior and the determination of these parameter regimes that result in immune-mediated tumor control.
Here, we focus on a particular tumor evasion regime that involves tumor and effector cell concentration
oscillations of slowly increasing and decreasing amplitude, respectively. Considering a temporal multiscale
analysis, we derive an analytically tractable mapping of model solutions onto a weakly negatively damped
harmonic oscillator. Based on our analysis, we propose a theory-driven intervention strategy involving
immunostimulating and immunosuppressive phases to induce long-term tumor control.
Introduction
The immune system is widely recognized for its capacity to detect and destroy cancer cells, as well as
to prevent tumor recurrence maintaining an immunological memory [1]. Indeed, every known innate
and adaptive immune effector mechanism has been reported that participates in tumor recognition and
rejection [2]. However, experimental observations support that tumorigenic processes themselves can
promote immunosuppression or immune tolerant states that facilitates neoplastic growth and progression
[3, 4]. Cancer cells employ diverse strategies to inhibit or block immune responses, including tumor-
induced impairment of antigen presentation, secretion of immunosuppressive cytokines or expression of
surface molecules, as well as production of diverse pro-apopoptic factors [5]. Nevertheless, there are
clinical and preclinical evidences supporting that activation of the innate antitumor immunity can result
in tumor regression and provide therapeutic benefits [6].
The main goal of oncoimmunology is to strengthen the immune system’s innate ability to combat
and kill cancer cells by enhancing the effectiveness of the immune responses. Among the different im-
munotherapeutic techniques are checkpoint inhibitors, immune response modifiers (cytokines), mono-
clonal antibodies and vaccines [7]. Passive and active immunotherapy has been successfully applied to
the treatment of a wide variety of human cancers [8] and holds promise of a lifelong cure [9]. However,
tumor-induced immunosuppression still represents a major obstacle to effective cell-mediated immunity
and immunotherapy [3, 5]. Accordingly, more insights into the main mechanisms associated with im-
mune responses based on tumor specific features are required to obtain successful therapeutic outcomes
with immunomodulatory strategies. Despite years of research devoted to understand the underlying
mechanisms of immune-tumor interactions, there are still many unanswered questions. In particular,
those related with the impact of tumor-associated vascularization on immune responses, as well as de-
termination of optimal and effective therapeutic protocols in cancer immunotherapy, are far from being
completely elucidated.
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2Mathematical oncology is a valuable descriptive and predictive analytic framework to address such
open questions. Continuum Mechanics concepts have been widely considered to investigate tumor growth
and therapy implications [10–14]. In addition, several mathematical models of tumor growth, where some
forms of the immune dynamics are often included, have been also extensively studied in the last years
[15–24]. Clinical data evidence that cancer cells can survive in a undetectable dormant state for extended
periods of time [25], which has been also predicted by several models of tumor-immune cell interactions [19,
20,22,26,27]. However, the neoplasm develops diverse strategies to circumvent the anti-tumor action of the
immune system [28,29]. In particular, this equilibrium state can be disrupted by different events affecting
the immune system which could result in tumor regrowth [29]. Sustained oscillations by the immune
system have been observed both in its healthy state and pathological situations [27,30,31]. Therefore, the
presence of an immune component in mathematical modeling has been described crucial for reproducing
clinically observed phenomena such as tumor dormancy, oscillations in tumor size and spontaneous tumor
regression [27,32–36]. Among the several reviews on the subject are those covering mathematical models of
tumor growth mainly focused on the cancer and immune system interactions [37–45]. The mathematical
modeling of the entire immuno-oncology dynamics is an enormously difficult and complex task. In
consequence, models describing interactions between growing tumors and immune dynamics should focus
on the crucial factors that are known to allow tumor escape from immuno-surveillance. Tumor-induced
angiogenesis is a crucial mechanism for cancer survival and proliferation, allowing a continuous supply
of oxygen and nutrients needed for tumor growth and progression [46–48]. However, the effectiveness of
antitumor immune responses is associated with the functional levels of the tumor blood vessels, which
allow a wider range of effector cell types to penetrate the tumor bulk and further exterminate cancer
cells [49,50]. These opposing effects demand for a mathematical model of vascularized tumor growth that
allows to explore the therapeutic potential of immunomodulatory interventions when innate immune
responses are insufficient for long-term tumor control.
The work herein reported intends to yield new insights in the potential of immunomodulatory inter-
ventions for cancer therapy. To this end, we propose a tumor-effector cell model based on well-known
biological assumptions that combines a model of radially symmetric tumor growth with an immune cell
recruitment model [20,32,51,52]. The main feature of our model is the modeling of the interplay between
functional tumor-associated vasculature and effector cell dynamics as described in [53]. Model results
predict that, depending on the functional tumor vascularization degree and effector cell recruitment
rate, long-term tumor control cannot be always reached. We particularly focus in such situations where
tumors escape immuno-surveillance to suggest an optimized theory-driven therapeutic strategy against
tumor growth. A temporal multiscale approach is then implemented to describe the tumor-immune sys-
tem interactions, where an analytically tractable approximation of the cancer-effector cell dynamics is
derived. We find that an efficient modulation of the immunostimulating and immunosuppressive phases
could induce long-term tumor control.
Mathematical model description
The present model describes the interactions between growing tumors and induced immune system dy-
namics. More precisely, the proposed tumor-effector cell model is a combination of a radial tumor
growth model and an effector cell recruitment model originally proposed in [51] and [32] respectively, see
also [20, 52, 54, 55]. The main feature is the low dimensional modeling of the complex interplay between
tumor-associated functional vasculature and immune recruitment dynamics as described in [53]. This
model can be interpreted as the temporal evolution of the average tumor radius, since radially symmetric
growth is not a realistic behaviour. The system variables are the average tumor radius R(t) and effector
cell concentration E(t) in the tumor vicinity.
3Radial tumor growth, R(t)
The temporal evolution of the average tumor radius is considered, where for simplicity invasive and
diffusive tumor properties are not taken into account. The tumor is modeled as an incompressible fluid
flowing through a porous medium, where tissue elasticity is simplified. The tumor-host interface is
assumed to be sharp and cell-to-cell adhesive forces are modeled as a surface tension at that interface.
The tumor expands as a mass whose growth is governed by a balance between cell birth (mitosis) and
death (apoptosis and necrosis). The mitotic rate within the tumor is assumed to be linearly dependent
on the nutrient concentration (oxygen, glucose, etc.) and is characterized by its maximal value λM
at the tumor-host interface. The death rate λA is uniform within the tumor and constant in time.
Moreover, we assume that the death rate λA reflects the lump effect of apoptotic/necrotic processes and
any other cell death inducing factor. The concentration of nutrients (e.g. oxygen or glucose) obeys a
reaction-diffusion equation in the tumor volume, where nutrients are supplied from the tumor-associated
functional vasculature and consumed by the tumor cells at a uniform consumption rate.
To gain insight on the impact of vascularization in tumor growth and immune responses, we assume
that the non-negative and dimensionless parameter B, where 0 ≤ B ≤ 1, represents the net effect of
functional tumor-associated vasculature on the tumor radius evolution. In the limit of avascular tumor
growth B = 0, such tumor-effector interactions take place only at the tumor surface. At the other
extreme, for B = 1 effector cells can potentially interact with any cancer cell within the tumor bulk.
Moreover, we consider an intrinsic length scale LD representing the average length of nutrient gradient,
i.e. supply, diffusion and consumption.
The efficacy of immune killing depends on the ability of effector cells to penetrate the tumor bulk via
the functional tumor-associated blood vessels. With improved vascularization, the effectors kill tumor
cells not only on the surface of the tumor, but also further inside [56]. We consider this process through a
phenomenological scaling function f(R,B) = R
B−1
RB−1+1 ∈ [0, 1], for B ∈ [0, 1), that models the penetration
of effector cells in the tumor parenchyma through the existing functional vasculature. This function
modulates the term related to tumor-effector cell interactions, such as killing of tumor cells due to
effectors represented by a rate c. Such scaling functions have been also considered in the classical von
Bertalanffy approach, and more recently in allometric models [57].
Taking these factors into account, we deduce the tumor radius R(t) dynamic under the assumption
of radial symmetry according to the following ODE equation:
dR
dt
=
1
3
(λMB − λA)R︸ ︷︷ ︸
net vascular
tumor growth
+λM (1−B)LD
(
1
tanh(R/LD)
− LD
R
)
︸ ︷︷ ︸
avascular
tumor growth
− cERf(R,B)︸ ︷︷ ︸
death due to
effector cells
(1)
where the time coordinate t has been omitted for notational simplicity, and λM , λA, LD and c are
non-negative constants.
Effector cell concentration, E(t)
We assume that effectors are recruited at a rate r depending on tumor cells following the Michaelis-Menten
kinetics, where K is a positive constant denoting the concentration at which the immune recruitment is
half-maximal. Effector cells die at a rate d0, and become inactivated a rate d1 due to their antitumor
activity. In particular, the inactivation of effectors by tumor cells is modeled through the function f(R,B)
described above. As functional vascularization increases, effectors can kill cancer cells throughout the
tumor bulk and tumor-immune cell interactions increase resulting in more inactivated immune cells.
Moreover, innate immunity or base immuno-surveillance is represented as a minimum presence of active
effector cells at any time given by an innate immune growth rate σ, even in the absence of tumor cells.
4The resulting ODE equation for the effector cell concentration E dynamic is given by:
dE
dt
= r
R3
K +R3
E︸ ︷︷ ︸
immune
recruitment rate
− d1ER3f(R,B)︸ ︷︷ ︸
effectors
inactivation rate
− d0E︸︷︷︸
effectors
death rate
+ σ︸︷︷︸
innate
immunity rate
(2)
where the time coordinate t has been omitted for sake of simplicity in the notation, and r, K, d0, d1
and σ are non-negative constants.
Model parameterization
Under the small tumor radius assumption, the very early tumor growth is always of exponential nature
and does not depend on the vascularization effects, i.e. parameter B, [52, 54, 58, 59]. Accordingly, we
assume that this initial growth depends exclusively on the net proliferation rate λp = (λM − λA) in the
absence of adaptive antitumor immune responses at those stages of growth, see the first term of Eq. (1).
Thus, considering experimental estimates of the growth rate at early phases of spheroids tumor growth
for the mouse colon carcinoma cell line CT26 as λp ≈ 1.20 day−1 [53, 60] and the physiological plausible
value λM = 1/18h = 1.34day
−1 for CT26 murine cells [53, 60, 61], we have that λA ≈ 0.14day−1. The
characteristic nutrient diffusion length has been experimentally estimated that ranges between 0.2 and
0.3 mm [53, 62–64]. The effector cell characteristic concentration is at the order of magnitude 105 cells.
The latter estimate is justified since the characteristic length scale of the system is at the order of 1.0 mm,
and given that cells are commonly assumed with a diameter between 10µm and 20µm [61], then for a
volume of 1mm3 the concentration is at the order of magnitude 105 cells. Moreover, we consider c = 0.03
cells−1 days−1 as measured from murine CT26 tumor growth experiments in [53], see also [20,32,55]. The
remaining parameter values d0 = 0.37 day
−1, d1 = 0.01 mm−3 days−1, K = 2.72 mm3 and σ = 0.13×105
cells days−1 are considered from previously reported experimental data [20, 32, 55, 65, 66], and properly
rescaled to the magnitudes and units considered in our model. Through a parameter sensitivity analysis,
we explore the effects on tumor growth of the effector cell recruitment rate r and functional vascularization
degree B for different choices of the initial tumor radius R0 and concentration of effector cells E0.
For convenience of the reader, we summarize in Tab. 1 the parameter values used in numerical simu-
lations of the tumor-immune dynamics considering the effect of tumor-associated vasculature.
Description Parameter Value Units Sources
Tumor mitotic rate λM 1.34 days
−1 [53, 60,61]
Tumor death rate λA 0.14 days
−1 [53, 60,61]
Characteristic nutrient diffusion length LD [0.2 - 0.3] mm [53,62–64]
Tumor cell kill by effectors c 0.03 cells−1 days−1 [20, 32,53,55]
Tumor volumen where r is half-maximal K 2.72 mm3 [20, 32,55,66]
Effectors inactivation rate by tumor cells d1 0.01 mm
−3 days−1 [20, 32,55,66]
Effectors death rate d0 0.37 days
−1 [20, 32,65,66]
Innate immune growth rate σ 0.13× 105 cells days−1 [20, 32,55,66]
Table 1: Model parameters. The effects of model parameters B and r, i.e. functional tumor-associated
vasculature and effector cell recruitment rate respectively, are investigated by a model sensitivity analysis.
Dynamical analysis of the model
In this section, we analyze the model’s behaviour with respect to two parameters, namely the effector
cell recruitment rate r and functional tumor-associated vasculature B.
5Fixed point analysis
The first step towards analyzing the model dynamics is the identification of the fixed points along with
their stability classification. Fig. 1(A-D) depicts the phase portraits of the system of equations (1)-(2) for
different values of the model parameter B, while keeping r constant and equal to 0.57 days−1. The black
curves represent the nullclines, i.e. curves along which dR/dt = 0 and dE/dt = 0, and the colored curves
the system trajectories for different initial conditions. The fixed points of the system are located at the
intersection of the nullclines. In each case, we identify the existence of two fixed points corresponding to
a low tumor radius (L = (RL, EL)) and a high tumor radius (H = (RH , EH)).
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Figure 1: Phase portraits and long-term characteristic dynamics. (A-D) Phase portraits of
the tumor radius R versus the concentration of effector cells E for different functional levels of the
tumor-associated vasculature B. The colored lines depict trajectories starting with the initial conditions
IC1 = (R0, E0) = (2.0 mm, 20×105 cells) (green) and IC2 = (R0, E0) = (2.0 mm, 10×105 cells) (purple),
respectively. The nullclines (zero-growth isoclines) of the dynamical system (black lines) are also plotted.
(E-H) Temporal evolution of R (red lines) and E (blue lines) which correspond to the trajectories in
panels (A-D) starting at the initial condition IC1. (I-L) Temporal evolution of R (red lines) and E (blue
lines) which correspond to the trajectories in panels (A-D) starting at the initial condition IC2. The
immune recruitment rate is r = 0.57 days−1 and the remaining parameters are as in Tab. 1.
Fig. 1(E-L) shows the evolution of the tumor radius and effector cells of the corresponding trajectories
on the phase plain, presented in Fig. 1(A-D). A quick glance at Fig. 1 reveals that the system trajectories
initiated near the L fixed point follow an oscillatory behavior with a slowly varying amplitude that can
be either increasing Fig. 1(F,G) or decreasing Fig. 1(E,H). This behavior indicates that, depending on
6the model parameter values, the L fixed point can be an attractor or a repellor. On the other hand, the
trajectories initiated away from this point follow an exponential behavior which results in a boundless
tumor growth while the amount of the effector cells fades out (see Fig. 1(I-L)).
To gain insight in the system behavior near the fixed points we construct the bifurcation diagrams with
respect to the model parameter r for different values of B (see Fig. 2(A-C)). The bifurcation diagrams
were calculated by performing an arc-length continuation method. This method is a special case of
numerical fixed-point continuation methods that ensures the continuation of solution branches at turning
points [67,68].
For sufficiently small values of r, we obtain that there are no fixed points, which consequently implies
that the tumor grows indefinitely. However, for a critical tumor radius rcr, a homoclinic bifurcation
occurs [69, 70] giving rise to two states: a lower branch which corresponds to the L fixed point, and an
upper branch which corresponds to the H fixed point. The local stability analysis shows that the H
fixed point is a saddle point, and therefore unstable. On the other hand, the L fixed point is a spiral
point which, depending on the value of the parameter B, can be unstable (spiral source) or stable (spiral
sink) [71,72]. Fig. 2(D,E) shows the local stability analysis of L and H for B = 0.60, which corresponds
to the bifurcation diagram in Fig. 2(B).
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Figure 2: Bifurcation diagrams with respect to r and local stability analysis. (A-C) One-
parameter bifurcation diagrams with respect to the effector cell recruitment rate r for different values of
the functional tumor-associated vasculature B (0.40, 0.60 and 0.95, respectively). The upper branches
correspond to the saddle point H, whereas the lower branches to the spiral point L. Solid lines depict
stable fixed points and dotted lines the unstable fixed points. (D) Eigenvalues of the Jacobian estimated
at the saddle point H with respect to the parameter r for B = 0.60. (E) Real part of the eigenvalues of
the Jacobian estimated at the spiral point L with respect to the parameter r for B = 0.60.
In the case of L being a spiral sink, a system trajectory initiated inside the homoclinic orbit, i.e. the
closed orbit which starts and returns to the saddle point in Fig. 3(A), will follow regular oscillations with
7a slowly decreasing amplitude until it reaches the fixed point. This implies that the tumor radius will stay
in a control bounded state. The homoclinic orbit defines the basin of attraction for the spiral sink [69,70].
Thus, any trajectory initiated outside the homoclinic orbit will result in an uncontrollable tumor growth
while the concentration of effector cells fades out. On the other hand, if L is a spiral source, any
initialization of the system close to L will produce regular oscillations with a slowly increasing amplitude.
This behavior persists until the trajectory of the system reaches the unstable manifold of the saddle point
H which drives the system towards an exponentially uncontrollable tumor evolution (see Fig. 3(B)).
1 2 3 4 510
20
30
40
Tumor Radius R (mm)
Ef
fe
cto
r c
ell
s E
 (x
 1
05
)
1             2             3            4             5
40
30
20
10
Homoclinic Orbit
1 2 3 4 510
15
20
25
30
Tumor Radius R (mm)
1             2             3            4             5
30
25
20
15
10
Ef
fe
cto
r c
ell
s E
 (x
 1
05
)
Unstable Manifold
     A                                                    B
C                                                     D
Figure 3: Classification of the system trajectories. (A) Homoclinic orbit of the saddle point H
(star) when the spiral point L (dot) is stable. (B) The unstable manifold of the saddle point H (star)
when the spiral point L (dot) is unstable
Interestingly, the time required for reaching the unstable manifold is significantly large. This system’s
behavior can be explained by performing a local stability analysis at the spiral point L. Fig. 4(A,B)
illustrates the stability of L when r is kept fixed and B is allowed to vary. The eigenvalues of the
Jacobian estimated at L are λ = µ ± iβ. When µ < 0, L is a spiral sink, while for µ > 0, L is a spiral
source. Fig. 4(C,D) shows how µ changes with respect to parameter B. For all values of the parameters
considered, we find that when L is a spiral source the real part of the eigenvalues is µ  1 with a
maximum value of µmax ∼= 5.5 × 10−3. Therefore, by setting µ =   1, we can identify two different
time-scales describing the system’s behavior: a fast time scale t where the regular oscillations occur and
a slow time scale T = t which describes the slowly varying amplitude. Fig. 5(A) depicts the variation
of β, which determines the oscillations frequency, with respect to the parameters r and B. Notice that
β ∈ (0, 1), i.e. β ∝ O(1).
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Figure 4: Stability analysis of the spiral point L with respect to parameter B. (A,B) Stability
analysis of L with respect to the functional tumor-associated vasculature B for the immune recruitment
rate r equal to 0.54 and 0.60 days−1, respectively. The labels S1 and S2 represent the bifurcation points,
while the solid and dashed lines depict the stable and unstable solution branches, respectively. (C) Real
part of the eigenvalues of the Jacobian estimated at the spiral point L with respect to B for r = 0.54
days−1. (D) Real part of the eigenvalues of the Jacobian estimated at the spiral point L with respect to
B for r = 0.60 days−1.
0.55 0.65 0.75 0.85
0.0
0.2
0.4
0.6
0.8
1.0
 
 
0.20
0.25
0.30
0.35
Recruitment rate r (days-1)
0.55         0.65          0.75          0.85
1.0 
0.8
 0.6
 0.4
0.2
0.0
0.5
0.4
0.3
0.2
U
S
Va
sc
ula
tu
re
 (B
)
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9A plausible question relates to the possibility of controlling tumor growth and with the conditions
under which this control can be achieved. The local stability analysis reveals that, when L is a spiral
sink, the homoclinic orbit creates a trapping region where the tumor remains controlled. However, when
L is a spiral source, the tumor will finally escape innate immune control, albeit the fact that it will stay
to a certain region for a long period of time. Therefore, a potential strategy aiming at controlling the
tumor growth would be to keep the tumor near the L fixed point. In the next sections, we show how an
external modulation of the immune system dynamics could be designed to limit the uncontrolled tumor
growth in the case that L is a spiral source.
Mapping to a negatively damped harmonic oscillator via multi-
scale analysis
The original model given by Eqs. (1)-(2) cannot be solved analytically and no control strategy can be
easily designed. For this reason, we employ a multiscale approach to analyze the system’s behavior
near the spiral point L. This approach, that efficiently describes the dynamics near a Hopf bifurcation
point, reveals the inherent multiscale structure of the problem by capturing the regular oscillations and
constructing an envelope of the slowly varying amplitude in deterministic [73] or stochastic nonlinear
systems [74–76]. Thus, adopting such an approach we are able to map the initial system to a simplified
negatively damped harmonic oscillator which allows to describe the self-sustained oscillations and the
system’s energy gain [77].
The system’s behavior near the spiral source L can be described by linearizing the Eqs. (1)-(2) around
R = RL and E = EL. Then, we obtain a new system of equations approximating the evolution of the
perturbations u and v given by:
u = R−RL, v = E − EL, (3)
for |u|  1 and |v|  1. Then, the linearized system takes the following form:
d
dt
(
u
v
)
≈ J|L
(
u
v
)
=
∂F∂R |L ∂F∂E |L
∂G
∂R |L ∂G∂E |L
 =
a1 a2
a3 a4
 , (4)
where J|L represents the Jacobian at the fixed point L and F,G correspond to the right-hand side of
Eqs. (1)-(2), respectively. The eigenvalues of the Jacobian are λ = Tr(J|L)/2±
√
(Tr(J|L))2 − 4D/2 =
µ ± iβ. Moreover, Tr(J|L) = a1 + a4 and D = a1a4 − a2a3 are the trace and determinant of the
Jacobian matrix, respectively. Since  = µ and β ∝ O(1), it follows that a1 ∝ O(), a4 ∝ O(),
whereas a2 ∝ O(1) and a3 ∝ O(1). Moreover, we observe that a1a4 ∝ O(2) which, consequently,
results in β =
√
(a1 + a4)2 − 4(a1a4 − a2a3)/2 ≈
√−a2a3. Thus, the eigenvalues can be approximated
by λ ≈ λˆ = ± iω, where ω = √−a2a3. The condition  1 holds for each case where L is a spiral source
and a2 is always negative since it represents the death rate of tumor cells. Therefore, we can approximate
the linearized system (4) by the following one which incorporates the different order-terms:
duˆ
dt
= uˆ+ a2vˆ,
dvˆ
dt
= a3uˆ+ vˆ,
(5)
where, uˆ ≈ u and vˆ ≈ v. The approximate linearized system (5) explicitly captures the different-order
terms and allows to draw analogies with the field of Mechanics. More precisely, the system (5) represents a
perturbed harmonic oscillator. The unperturbed problem (i.e. when  = 0) is a linear harmonic oscillator
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with frequency ω. The higher-order terms (or correction terms) insert small perturbations which result
in a weakly negatively damped harmonic oscillator.
The solution of the approximate system (5) can be expressed as:(
uˆ
vˆ
)
= A(T )
(
a2
ω sin(ωt)
cos(ωt)
)
+B(T )
(
a2
ω cos(ωt)− sin(ωt)
)
, (6)
where A(T ) and B(T ) contain the information regarding the slowly varying amplitude depending on T ,
where T = t for   1. The multiscale assumption is that the functions A(T ) and B(T ) evolve at the
slow time scale T and are considered to be constant with respect to the oscillations with frequency ω,
evolving on the fast time scale t. Notice that the variables T = t ∝ O() and t ∝ O(1) are considered to
be independent. The constant term a2/ω in the expression of uˆ has been used to simplify the upcoming
calculations.
In order to estimate the functions A(T ) and B(T ), we assume that they follow evolution equations of
the form:
dA = f1dT, dB = f2dT. (7)
Then, by taking the differentials of the system of equations in (6), we have that:
duˆ =
∂uˆ
∂t
dt+
∂uˆ
∂A
dA+
∂uˆ
∂B
dB
= a2vˆ dt+
(
f1
a2
ω
sin(ωt) + f2
a2
ω
cos(ωt)
)
dT,
dvˆ =
∂vˆ
∂t
dt+
∂vˆ
∂A
dA+
∂vˆ
∂B
dB
= a3uˆ dt+ (f1 cos(ωt)− f2 sin(ωt)) dT.
(8)
Notice that the system of equations in (5) and (8) are equivalent. Therefore, by equating the terms which
are of the same order, we obtain that:
f1
a2
ω
sin(ωt) + f2
a2
ω
cos(ωt) = A(T )
a2
ω
sin(ωt) +B(T )
a2
ω
cos(ωt), (9)
f1 cos(ωt)− f2 sin(ωt) = A(T ) cos(ωt)−B(T ) sin(ωt). (10)
To estimate the functions f1 and f2, we project the Eqs. (9)-(10) onto the fast dynamics. This is an
important step of the calculations in order to isolate the amplitude of functions f1 and f2 [75, 76]. For
instance, multiplying Eq. (9) by sin(ωt) and integrating over a period of time [0, 2pi/ω] , we have that:
∫ 2pi/ω
0
(
f1
a2
ω
sin(ωt) + f2
a2
ω
cos(ωt)
)
sin(ωt)dt
=
∫ 2pi/ω
0
(
A(T )
a2
ω
sin(ωt) +B(T )
a2
ω
cos(ωt)
)
sin(ωt)dt,
which results in f1 = A. In a similar way, multiplying Eq. (9) by cos(ωt) and following the same procedure,
we find f2 = B. Consequently, the solution of the approximate linearized system (5) is given by:(
uˆ
vˆ
)
= A0e
T
(
a2
ω sin(ωt)
cos(ωt)
)
+B0e
T
(
a2
ω cos(ωt)− sin(ωt)
)
, (11)
where the positive parameters A0 and B0 are defined by the initial conditions of the original model
(1)-(2). In addition, Eq. (11) can be further simplified to take the following form:
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(
uˆ
vˆ
)
=
(
MeT sin(ωt+ φ)
NeT sin(ωt+ δ)
)
, (12)
where M cos(φ) = A0 a2/ω, M sin(φ) = B0 a2/ω, N sin(δ) = A0 and N cos(δ) = −B0. We show that the
functions uˆ and vˆ are orthogonal since:
cos(δ − φ) = cos(δ) cos(φ) + sin(δ) sin(φ) (13)
=
−B0
N
A0
M
a2
ω
+
A0
N
B0
M
a2
ω
= 0 (14)
⇔ δ = φ+ pi
2
. (15)
Then, the system of the approximate solutions becomes:(
uˆ
vˆ
)
=
(
MeT sin(ωt+ φ)
NeT cos(ωt+ φ)
)
. (16)
The advantage of using the proposed approach is that the solutions of the approximate model (16)
depend directly on experimentally accessible parameters and the initial conditions. We focus now on the
stability properties of the system (5) with respect to the time evolution of the variables uˆ and vˆ. To that
end, we construct a Lyapounov functional as:
V (uˆ, vˆ) =
1
2
(
a3uˆ
2 − a2vˆ2
)
, (17)
where V is always positive definite since a2 < 0, and the time-derivative of V is given by:
dV
dt
= a3uˆ
duˆ
dt
− a2vˆ dvˆ
dt
= 
(
a3uˆ
2 − a2vˆ2
)
+ (a3a2uˆvˆ − a3a2uˆvˆ)
= 
(
a3uˆ
2 − a2vˆ2
)
> 0.
(18)
Since dV/dt > 0 the system gains energy. The average energy 〈V 〉 over a period is estimated by using
the form of the approximate solutions (12) and considering the multiscale assumption:
〈V 〉 =
∫ 2pi/ω
0
V dt =
1
2
(
a3uˆ
2 − a2vˆ2
)
dt ≈ e2T 1
4
(
a3M
2 − a2N2
)
. (19)
The term 14
(
a3M
2 − a2N2
)
is constant and depends on time-invariant parameter values and the initial
conditions. Consequently, the average energy gain rate over a period is equal to:
d〈V 〉
dt
= 2〈V 〉. (20)
The previous results suggest that a therapeutic strategy, which influences the effector cell dynamics,
should be designed in a way to “pump out energy” with an average rate which is greater than the system’s
gain energy. In particular, the per period gain rate is equal to 2 according to relation (19). Thus, if we
introduce an external immune-modulatory term h(vˆ) to intervene in the tumor-effector cell interactions,
the system of equations (5) becomes:
duˆ
dt
= uˆ+ a2vˆ,
dvˆ
dt
= a3uˆ+ vˆ + h(vˆ).
(21)
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According to Eq. (18), the rate dV/dt is at most of the order of O(). Therefore, the function h(vˆ) should
be of the order of O(), for instance:
h(vˆ) = zˆ(t). (22)
In order to calculate the function zˆ(t), we require that the energy Vh of the system (21) should have
a negative rate, that is:
dVh
dt
= a3uˆ
duˆ
dt
− a2vˆ dvˆ
dt
= 
(
a3uˆ
2 − a2vˆ2 − a2vˆzˆ(t)
)
+ (a3a2uˆvˆ − a3a2uˆvˆ)
= 
(
a3uˆ
2 − a2vˆ2 − a2vˆzˆ(t)
) ≤ 0.
(23)
The negative energy rate means that a trajectory will flow “downhill” towards a stable fixed point. In
the limit dVh/dt = 0, we find an expression for the zero-rate energy function zˆ(t) in terms of the solutions
uˆ and vˆ, given by:
zˆ(t) =
a3uˆ
2 − a2vˆ2
a2vˆ
. (24)
Substituting the solutions of uˆ and vˆ from Eq. (16), we have an analytical expression of the zero-rate
energy function zˆ(t), that is:
zˆ(t) =
a3
a2
M2
N
eT tan(ωt+ φ) sin(ωt+ φ)−MeT cos(ωt+ φ). (25)
The function zˆ(t) has singularities at the points where the function cos(ωt + φ) is equal to zero, i.e.
tsing =
(
κpi + pi2 − φ
)
/ω, κ = 0, 1, 2, .... However, the effect of zˆ(t), i.e. the integral of the function within
a small time interval [t1, t2] ⊂ [0, 2pi/ω], is finite.
Fig. 6 illustrates the effect of zˆ(t) by integrating between t = 0 and t = pi/ω, for values of the model
parameters r and B where L is unstable. In each case, the system was initialized near the spiral point L.
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Figure 6: Dependence of the zero-rate energy function zˆ(t) effect on model parameters B and
r. Dependence of the effect of zˆ(t) on the immune recruitment rate r and functional tumor-associated
vasculature B in the unstable regime of L denoted by U. The label S stands for the regime where the
spiral point is stable and tumor control is reached.
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Using the function zˆ(t) is not feasible for practical purposes. However, we can design meaningful
therapy functions zˆext(t) that induce the same or greater effects in a certain time interval [t1, t2] as the
function zˆ(t), that is: ∫ t2
t1
zˆ(t)dt ≤
∫ t2
t1
zˆext(t)dt. (26)
This will result in “pumping out energy” at a rate greater than the system’s energy gain. In the
next section, we estimate the function zˆ(t) which represents the zero-rate energy scenario, as well as we
present numerical simulation results for specific values of the model parameters. Furthermore, based on
the behavior of the function zˆ(t), we suggest an efficient external immune-modulatory term zˆext(t) to
fulfill the relation (26) which results in long-term tumor control.
Results: theory-driven therapeutic design
In this section, we design an immuno-therapeutic proposal derived from our model analysis. We first
compare the approximate solutions with those obtained from the original model (1)-(2). Then, we
show how the defined energy function in Eq. (17) for the approximate linearized system can be used to
describe the system’s energy gain. Finally, we design an external immuno-modulatory strategy following
the behavior of the zero-rate energy function given in Eq. (25).
To illustrate the simulation results and without loss of generality, we select the following parameter
values: r = 0.6 days−1 and B = 0.8, which result in  = 5.85 · 10−4 and ω = √−a2a3 = 0.336 rad/days.
Notice that similar results can be obtained for each parameter set where L is a spiral source, since  1
always holds. For numerical integration, we consider a 4th order Runge-Kutta method. The time step
was set equal to dt = 0.001 days which is sufficiently small.
Validity of approximate solution
At this point, we need to validate the performance of the approximate solutions. Fig. 7(A) depicts the
evolution of the approximate perturbation uˆ compared to the perturbation u = R − RL of the initial
model given by Eqs. (1)-(2), referred in what follows as original model perturbation. The approximate
solutions uˆ were estimated by performing a numerical integration of the system (5), while u = R − RL
by numerically integrating the original model (1)-(2). Both systems of equations were initialized close
to the spiral point L and the simulation time was set tsim = 1000 days. A quick glance at Fig. 7(A)
reveals that the solution derived by the approximate model (5) is very close to the original one, which
demonstrates the validity of the approach. Moreover, Fig. 7(A) shows a comparison of the original and
approximate model solutions by zooming in the time interval between days 400 and 425. In this interval,
the maximum error between such solutions was found to be of the order of 10−3.
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Figure 7: Validation of approximate solutions. (A) Evolution of the approximate perturbation uˆ
compared to the original model perturbation u = R − RL. (B) Evolution of the energy function of
the approximate linearized model defined in Eq. (17) against the energy estimated by using the original
model (1)-(2). (C) The zero-rate energy function in Eq. (24) estimated by using the approximate solution
of the system (13). (D) The immuno-modulatory function zˆext(t) for α = −0.6 and γ = 100 compared
with the zero-rate energy function zˆ(t).
Fig. 7(B) compares the evolution of the approximate energy function defined in Eq. (17) against the
energy of the original model (1,2). As in the previous case, the energy function of the approximation is
in a good agreement with that obtained from the original model. Therefore, we expect that an external
immune-modulatory strategy, which results in a negative energy rate, can be used with the same efficacy
to the original model.
Construction of the therapy term
Fig. 7(C) depicts the zero-rate energy function in Eq. (24) estimated by using the approximate solutions
uˆ and vˆ from the system (21). As we observe, this function diverges at the singularity points, which
means that it cannot be used directly to induce tumor control.
It should be noted that, the zero-rate energy function changes sign according to the evolution of the
variable u = R − RL, i.e. the function follows the monotonicity of tumor evolution. Hence, an external
immuno-modulatory therapy zˆext(t) that satisfies the condition (26) should follow the evolution of the
tumor by increasing the recruitment rate of effector cells when the tumor radius increases and decreasing
the immune recruitment rate when the tumor radius decreases. A simple approximation of the therapy
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function would be a step function having a constant value and the same sign to the zero-rate energy
function at the same time interval:
zˆext(t) = α tanh(γvˆ), (27)
where γ  1 expresses the sigmoidal steepness, and the selection of α should fulfill the relation (26).
Fig. 7(D) depicts the immuno-modulatory function zˆext(t) for α = −0.6 and γ = 100, compared with the
zero-rate energy function zˆ(t) estimated.
Performance of the suggested therapy
The application of the external therapy in Eq. (27) implies the addition of a new term in Eqs. (1)-(2),
that is:
dR
dt
=
1
3
(λMB − λA)R+ λM (1−B)LD
(
1
tanh(R/LD)
− LD
R
)
− cERf(R,B), (28)
dE
dt
= r
R3
K +R3
E − d1ER3f(R,α)− d0E + σ + α tanh(γv(t)), (29)
where v(t) = E(t)− EL.
Fig. 8(A,B) respectively shows the evolution of the tumor radius and effector cells by numerically
integrating Eqs. (28)-(29) which include the proposed external immuno-modulatory function (27). The
system is initialized near the spiral point L and parameter values of the external function were selected
equal to α = −0.6 and γ = 100. In doing so, we obtain that the system reaches a stable steady state,
i.e. the tumor remains controlled. Fig. 8(C) illustrates how the energy of the system of Eqs. (28)-(29)
evolves. The energy decreases with time and becomes zero as the system reaches the steady state. It
is worth pointing out that α was selected not only to satisfy the relation (26), but also to result in the
system’s fast convergence to a steady state.
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Figure 8: Performance of the proposed therapy term. Evolution of the tumor radius (A) and
concentration of effector cells (B) by considering the external immuno-modulatory function (27) with
parameters α = −0.6 and γ = 100. (C) Energy of the system of Eqs. (28)-(29) with α = −0.6 and
γ = 100. Evolution of the tumor radius (D) and concentration of effector cells (E) by initializing the
system away from the spiral point L and considering the external immuno-modulatory function with
α = −25 and γ = 100. (F) Energy of the system of Eqs. (28)-(29), with α = −25 and γ = 100, initialized
away from the spiral point L.
Fig. 8(D,E) respectively shows the evolution of the tumor radius and concentration of effector cells
by numerically integrating Eqs. (28)-(29) when the system is initialized away from the spiral point L.
In this case, the approximate solution is expected to deviate from the solutions of the original model.
Fig. 8(F) represents the temporal evolution of the corresponding energy. The parameter α was selected
to be equal to −25 to fulfil the relation (26), as well as to provide a fast convergence to a steady state.
Interestingly enough, in this case the system also reaches a steady state, even though the approximate
system is not accurate enough. Consequently, the proposed external immuno-modulatory function is
shown to be adequate in controlling tumor growth, even when the system is initialized far to the spiral
point L.
Discussion
In this article, we investigate the therapeutic potential of immunomodulatory interventions against tumor
growth. To that end, we consider a model introduced in [53] that describes the dynamic interplay between
vascularized tumor growth and effector cell responses. Our goal is to identify an external modification
of effector cell dynamics that allows for controlling tumor growth. With the help of bifurcation analysis,
we identified a unstable oscillatory regime that induces tumor evasion from immuno-surveillance. The
characteristic feature of this regime is the oscillations occur at a faster time scale than the amplitude
dynamics. Exploiting this time scale separation and via temporal multiscale analysis, we map our model
onto a weakly negatively damped harmonic oscillator. This approximation allowed us to identify an
analytical expression for the additive control term to the effector cell dynamics. This term acts as an
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external immunomodulatory therapy where the numerical simulations evidence its efficacy in controlling
tumor growth.
The crucial question concerns the translational potential of our theory-driven therapeutic proposal into
clinical practice. Our suggested immunomodulatory strategy is relevant to small enough, non-invasive
tumors that are initially controlled by the immune system but eventually evade immuno-surveillance.
The latter occurs when tumors exceed a critical size where immune responses are unable to confer any
control. As stated above, our model suggests that such tumor evasion may take place in the form of
oscillations of slowly increasing amplitude. The proposed therapeutic strategy is based on the syn-
chronization of immuno-stimulating and -suppressive phases with tumor growth dynamics. Although
immuno-stimulating therapies seem to be expected and plausible [6, 8], immuno-suppression sounds
counter-intuitive and dangerous. However, the latter occurs in clinical practice during chemotherapeutic
interventions [78]. Therefore, a potential realization of our proposed strategy could be mediated by a com-
bination of state-of-the-art immunotherapies [1, 4, 8, 49] and chemotherapeutic modules. The latter not
only will play the role of immuno-suppressor, but also will slow down tumor growth dynamics. Needless
to state that such a therapeutic suggestion requires experimental validation and further investigation.
Finally, we conclude by pointing out the limitations of the present work. Paramount among them,
introducing vascularization dynamics should be not only a natural, but also an insightful extension of
the proposed model. At this state tumor vascularization B is considered as a constant parameter in
time. Thus, making vascularization dynamic would make sense to model further hypoxic effects, such as
necrosis or hypoxic-induced invasion. Moreover, the immune system is much more complicated than its
description in the current model, involving much more cell types and interactions. In particular, immune
system is often regarded as acting to suppress tumor growth, however it is now clear that it can be both
stimulatory and inhibitory, as in the case of tumor-associated macrophages [79,80]. Moreover, our model
needs be extended for invasive tumors. Nevertheless, mathematical modeling can help to improve our
understanding of the interplay between the several competing factors that have complex implications for
cancer therapy. We hope that the model presented here could provide a step towards this direction.
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